SCHEMBL540949

SCHEMBL540949

CCCC1C[N]CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9820594 0.88 EPHX1 (0.48)
SCHEMBL4556954 0.86 EPHX1 (0.57)
SCHEMBL9820564 0.84 EPHX1 (0.60)
SCHEMBL8751032 0.82
SCHEMBL8751150 0.82
SCHEMBL232761 0.82
SCHEMBL2917852 0.78
SCHEMBL2918392 0.78
SCHEMBL2911511 0.78
SCHEMBL2920970 0.78 LMNA (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023225311-A1 1,4,5-TRISUBSTITUTED-1,2,3-TRIAZOLES AND USES THEREOF UNIVERSITY OF PUERTO RICO (PR) 2023-11-23 WO claimed
EP-3128995-A1 SOLUBLIZING AGENTS FOR UV FILTERS IN COSMETIC FORMULATIONS BASF SE (DE) 2017-02-15 EP claimed
US-20170027831-A1 SOLUBLIZING AGENTS FOR UV FILTERS IN COSMETIC FORMULATIONS BASF SE (DE) 2017-02-02 US claimed
WO-2015155095-A1 SOLUBLIZING AGENTS FOR UV FILTERS IN COSMETIC FORMULATIONS BASF SE (DE) 2015-10-15 WO claimed
US-8898047-B2 Methods for identifying inhibitors against viruses that use a class I fusion protein JANSSEN PHARMACEUTICALS NV (BE) 2014-11-25 US claimed
EP-2257809-B1 METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN TIBOTEC PHARM LTD (IE) 2012-02-08 EP claimed
US-20110009408-A1 METHODS FOR IDENTIFIYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN JANSSEN SCIENCES IRELAND UC (IE) 2011-01-13 US claimed
EP-2257809-A1 METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN Tibotec Pharmaceuticals (IE) 2010-12-08 EP claimed
WO-2009106580-A1 METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN TIBOTEC PHARMACEUTICALS (IE) 2009-09-03 WO claimed
US-20090149648-A1 NUCLEOTIDE ANALOGS GILEAD SCIENCES, INC. (US) 2009-06-11 US claimed
US-7476672-B2 Acetylenic compounds useful in treating inflammatory disorders JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-13 US claimed
US-20060111352-A1 Acetylenic compounds useful in treating inflammatory disorders BEERS SCOTT 2006-05-25 US claimed
US-20050020838-A1 Acetylenic compound useful in treating inflammatory disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2005-01-27 US claimed
WO-2004009531-A1 ACETYLENIC COMPOUNDS USEFUL IN TREATING INFLAMMATORY DISORDERS JANSSEN PHARMACEUTICA N.V. (BE) 2004-01-29 WO claimed
EP-0377139-B1 N-substituted acylamino acid compounds, process for their production and their use BANYU PHARMA CO LTD (JP) 1995-07-12 EP claimed
WO-2023225311-A1 1,4,5-TRISUBSTITUTED-1,2,3-TRIAZOLES AND USES THEREOF UNIVERSITY OF PUERTO RICO (PR) 2023-11-23 WO disclosed
WO-2023084516-A1 NOVEL CANNABINOID DERIVATIVES CANNASOUL ANALYTICS LTD. (IL) 2023-05-19 WO disclosed
EP-0063826-A2 2-Amino-benzoic-acid derivatives, their preparation and their use as medicines or intermediates Dr. Karl Thomae GmbH (DE) 1982-11-03 EP disclosed
EP-0055444-A2 Trisubstituted pyrimido(5,4-d)pyrimidines, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1982-07-07 EP disclosed
EP-0023569-A1 Derivatives of carboxylic acids, their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1981-02-11 EP disclosed